Funding sources: none. Conflicts of interest: E.M. is a consultant for AbbVie, Janssen‐Cilag, Novartis and Pfizer; is an investigator for Pfizer, Amgen, Novartis and LEO Pharma; and has received speaker honoraria from AbbVie, GSK, Janssen‐Cilag, Novartis and Pfizer. F.B. has received speaker honoraria from LEO Pharma. J.M.‐H. is a consultant for Actavis (Soriatane®). F.A. has been a consultant for Janssen‐Cilag, Pfizer, MDS, AbbVie and Celgene; and is an investigator for AbbVie, Amgen and Novartis. The other authors declare no conflicts of interest. Dear Editor, Psoriasis is a common, chronic, systemic inflammatory disease mediated by T lymphocytes.1 The main clinical presentation is plaque psoriasis.2 The incidence of psoriasis in the childhood population is estimated at 40·8 per 100 000, and the median age of onset among children is 7–10 years.3 In Europe psoriasis affects 0·5–1% of children.4 The physical, psychological and social impact of psoriasis and the association with comorbidity highlight the need for early management.5 6 7
No takes yet. Share an insight, caveat, or question.
Charbit et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: